Business News • MarketWire • Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Lpath Temporarily Suspends Dosing of iSONEP in Clinical Trials Due to cGMP Compliance Issues at Contract Fill/Finish Source

Management to Host Investor Conference Call Tomorrow, Friday, January 27 at 8:45 a.m. ET

View More : http://www.marketwire.com/mw/release.do?id=1611710&sourceType=3

Releted News by marketwire

Idaho First Bank Reports Year-End Results and Continued Quarterly Income

eHealth, Inc. Addresses States, Industry at 2012 Health Insurance Exchange Summit